comscoreBreast Cancer Research at ESMO 2020

Breast Cancer Research at ESMO 2020

Michael Method, MD, discusses the breast cancer research out of ESMO Congress 2020.
Oct 16, 2020
00:00
Download
00:00

While ESMO 2020 was virtual this year, there was still quite a bit of breast cancer research presented. Dr. Method joined us to talk about some of the most notable studies.

Listen to the podcast to hear him discuss:

  • studies looking at using the CDK4/6 inhibitors Verzenio (chemical name: abemaciclib) and Ibrance (chemical name: palbociclib) to treat early-stage hormone-receptor-positive, HER2-negative breast cancer

  • a study using the immunotherapy Tecentriq (chemical name: atezolizumab) to treat early-stage triple-negative breast cancer before surgery

About the guest
 
Michael Method headshot
Michael Method, MD

Dr. Michael Method is an oncologist and also senior medical adviser and global lead for adjuvant breast cancer treatment research at Lilly Oncology.

— Last updated on February 7, 2022, 3:51 PM

 
Lilly Oncology

This podcast episode made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate